# OvaScience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ovascience

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.ovascience.com
- Total disclosed funding: $43M
- Latest round: Series B (Mar 28, 2012)
- Investors on record: 7

## About

OvaScience, Inc. focuses on advancing reproductive health by developing innovative treatments for infertility, emphasizing the utilization of advanced cellular technologies to improve outcomes for prospective parents.OvaScience, Inc. was founded in 2011 and is based in Waltham, US. The company specializes in creating solutions for infertility, employing advanced cellular therapies. OvaScience has undergone significant funding initiatives, including a Private Placement/Follow on round where it raised USD 53.80 mn in May 2016, and previously raised USD 132.30 mn in January 2015. Notably, a reverse merger with Millendo Therapeutics, Inc. was completed in December 2018, allowing OvaScience to operate under the Millendo name. The company has been involved in a total of 9 funding deals with the most recent deal occurring on March 4, 2014.OvaScience, Inc. develops innovative fertility treatments that leverage advanced cellular technologies to enhance reproductive health. Their proprietary platform aims to increase the chances of conception and improve the outcomes of assisted reproductive techniques, specifically targeting women facing infertility issues. The company focuses on research and development to provide effective solutions tailored to the needs of patients seeking support in their reproductive journeys.In the most recent financial year of 2017, OvaScience reported a revenue of USD 295,000. The company's EBITDA for the same year stood at USD -48,897,000, reflecting significant operational challenges faced during that period.Looking ahead, OvaScience, Inc. aims to expand its product offerings and enhance its existing fertility treatments. The company plans to invest in the development of new therapies to improve success rates for patients undergoing fertility treatments. Recent funding will be directed towards R&D initiatives and exploring potential market expansion in North America and Europe by the end of 2023. The funds raised through the successful Private Placement/Follow on round will support these strategic objectives, allowing OvaScience to solidify its presence in the reproductive health sector.

## Funding rounds

- Series B, Mar 28, 2012, $37M — General Catalyst Partners, Cycad Group, Bessemer Venture Partners, Hunt BioVentures, Longwood Fund, BBT Capital Management, RA Capital Management
- Series A, Jul 1, 2011, $6M — Bessemer Venture Partners, Longwood Fund

## Investors

- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series A, Series B
- Longwood Fund (https://capitalatlas.ai/funds/longwood-fund) — Series A, Series B
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series B
- Cycad Group (https://capitalatlas.ai/funds/cycad-group) — Series B
- Hunt BioVentures (https://capitalatlas.ai/funds/hunt-bioventures) — Series B
- BBT Capital Management — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B